2024
Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors. JAMA Oncology 2024, 10: 887-895. PMID: 38753341, PMCID: PMC11099840, DOI: 10.1001/jamaoncol.2024.1129.Peer-Reviewed Original ResearchNational Quality ForumQuintile 5Quintile 1Improve end-of-life careEnd-of-life careCohort studyNationwide population-based cohort studyPopulation-based cohort studyEnd of lifeElectronic health record databaseHealth care practicesColorectal cancerPopulation of patientsCox proportional hazards modelsAmerican Society of Clinical OncologyQuality ForumCare practicesOverall survivalPayment incentivesProportional hazards modelHighest quintileMultivariate Cox proportional hazards modelQuintileFlatiron HealthHazard ratio
2019
1558P Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)
Cohen A, Neri B, Adamson B, Scanlon C, Gross C, Meropol N, Miksad R. 1558P Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC). Annals Of Oncology 2019, 30: v642. DOI: 10.1093/annonc/mdz260.080.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerFlatiron HealthOverall survivalBiomarker statusOlder ptsNon-small cell lung cancerAge groupsFred Hutchinson Cancer Research CenterMedian overall survivalNon-squamous histologyCell lung cancerProportional hazards regressionReal-world populationCancer Research CenterAge-related outcomesPDL1 statusLonger OSSimilar OSStage IIIBBaseline characteristicsMetastatic NSCLCPrognostic factorsSmoking statusHazards regressionLung cancer